Zevra Completes Acquisition of Acer Therapeutics: Read More Here.

Zevra.com
Olpruva.com
Remain on Acertx.com

Press Releases

Investor Relations

Filter by Year

August 7, 2014

FDA Grants Orphan Drug Designation to ACER-001

The U.S. Food and Drug Administration Grants Orphan Drug Designation to ACER-001 for the Potential Treatment of Maple Syrup Urine Disease In August 2014, Acer Therapeutics Inc., a pharmaceutical company developing therapies for serious rare diseases with significant unmet medical need, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) to […]

Read More
April 7, 2014

Acer Therapeutics Licenses Exclusive Worldwide Rights

Acer Therapeutics Licenses Exclusive Worldwide Rights from Baylor College of Medicine for Development of Sodium Phenylbutyrate for Maple Syrup Urine Disease In April 2014, Acer Therapeutics Inc. entered into an exclusive worldwide license agreement with Baylor College of Medicine to develop and commercialize formulations and prodrugs of sodium phenylbutyrate for the treatment of Maple Syrup […]

Read More
QUICK
NAV